BioSpace News Archive

OKYO Pharma Limited announced that it has received clearance of its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of DED.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022.

IASO Biotherapeutics announced that the Investigational New Drug application for its in-house developed BCMA CAR-T CT103A has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for relapsed/refractory multiple myeloma.

BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the companies provided approximately 11,500 doses of mRNA-based COVID-19 vaccines which arrived on the Chinese Mainland on December 21, 2022.

ProQR Therapeutics N.V. today announced that ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.

Merck and Kelun-Biotech today announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.

Pluri Inc., a leading biotechnology Company, issued the following update to shareholders from CEO and President Yaky Yanay and announced that as planned the Company’s joint venture with Tnuva Group has successfully achieved proof of concept in its development of cultivated meat based on Pluri’s proprietary 3D cell-based technology platform.

Orthofix Medical Inc. today announced results from a prospective, multicenter clinical study evaluating the safety and efficacy of the Trinity Elite ™ cellular bone allograft (CBA) in lumbar spinal fusion procedures.

Oragenics, Inc. today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.